DICE Therapeutics, Inc. (NASDAQ:DICE) Receives Consensus Rating of “Buy” from Analysts

DICE Therapeutics, Inc. (NASDAQ:DICEGet Rating) has received an average rating of “Buy” from the six analysts that are covering the company, MarketBeat.com reports. Six investment analysts have rated the stock with a buy rating. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $43.33.

DICE has been the subject of a number of analyst reports. HC Wainwright initiated coverage on DICE Therapeutics in a research note on Monday, July 18th. They set a “buy” rating and a $40.00 target price for the company. Stifel Nicolaus initiated coverage on DICE Therapeutics in a research note on Tuesday, September 6th. They set a “buy” rating and a $37.00 target price for the company. Finally, Cantor Fitzgerald initiated coverage on DICE Therapeutics in a research note on Wednesday, September 14th. They set an “overweight” rating and a $36.00 target price for the company.

DICE Therapeutics Trading Down 0.2 %

DICE Therapeutics stock opened at $19.98 on Wednesday. DICE Therapeutics has a twelve month low of $12.64 and a twelve month high of $40.50. The stock has a 50 day moving average of $18.22 and a two-hundred day moving average of $17.68. The stock has a market capitalization of $763.46 million and a price-to-earnings ratio of -5.23.

Hedge Funds Weigh In On DICE Therapeutics

Hedge funds have recently bought and sold shares of the company. Prospera Financial Services Inc purchased a new position in DICE Therapeutics in the 1st quarter valued at approximately $39,000. Amalgamated Bank purchased a new position in DICE Therapeutics in the 1st quarter valued at approximately $39,000. Legal & General Group Plc increased its stake in DICE Therapeutics by 265.1% in the 2nd quarter. Legal & General Group Plc now owns 4,764 shares of the company’s stock valued at $74,000 after purchasing an additional 3,459 shares in the last quarter. Virtus ETF Advisers LLC increased its position in DICE Therapeutics by 18.5% during the second quarter. Virtus ETF Advisers LLC now owns 7,482 shares of the company’s stock worth $116,000 after buying an additional 1,166 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new position in DICE Therapeutics during the second quarter worth $131,000. 95.42% of the stock is owned by hedge funds and other institutional investors.

About DICE Therapeutics

(Get Rating)

DICE Therapeutics, Inc, a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics.

Featured Stories

Analyst Recommendations for DICE Therapeutics (NASDAQ:DICE)

Receive News & Ratings for DICE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DICE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.